预约演示
更新于：2025-03-05
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-03-05
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
109
项与 洛索洛芬钠 相关的临床试验ChiCTR2500097025
Postoperative application of loxoprofen sodium tablets for the prevention of post-implantation syndrome after thoracic endovascular aortic repair: A single-center, prospective, randomized controlled study
CTR20250487
洛索洛芬钠贴剂人体生物等效性研究
CTR20244943
洛索洛芬钠贴剂人体生物等效性研究
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
1,343
项与 洛索洛芬钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study
Article
作者: Zhang, Jinying ; Liu, Naifeng ; Fang, Lijuan ; Wang, Zhenwei ; Shi, Qian ; Tang, Junnan
AIMS:
To assess the link between persistent lipoprotein(a) [Lp(a)] exposure levels and clinical outcomes in patients with acute myocardial infarction (AMI).
METHODS:
This longitudinal cohort study included 1131 AMI patients, categorizing persistent Lp(a) exposure based on measurements at admission and after 1 year. Patients were segmented into four groups using a 300 mg/L Lp(a) threshold: (1) persistent low Lp(a) (lowon admission - lowat 1 year); (2) fortified Lp(a) (lowon admission - highat 1 year); (3) attenuated Lp(a) (highon admission - lowat 1 year); and (4) persistent high Lp(a) (highon admission - highat 1 year). Multivariate Cox regression, subgroup analysis and sensitivity analysis assessed the association between Lp(a) trajectories and major adverse cardiovascular and cerebrovascular events (MACCE), cardiovascular death, non-fatal MI, non-fatal stroke, unplanned revascularization, and all-cause death.
RESULTS:
Over a median 50-month follow-up, 343 (35.70%) patients encountered MACCE, and 210 (18.70%) died, including 126 (11.20%) from cardiovascular causes. The group with persistent high Lp(a) faced increased risk of MACCE (HRadjusted, 1.871; 95% CI: 1.474-2.374), non-fatal stroke (HRadjusted, 1.647; 95% CI: 1.031-2.632), unplanned revascularization (HRadjusted, 1.571; 95% CI: 1.008-2.449), and both all-cause (HRadjusted, 1.546; 95% CI: 1.134-2.108) and cardiovascular death (HRadjusted, 2.163; 95% CI: 1.405-3.331), compared to the persistent low Lp(a) group.
CONCLUSIONS:
In AMI patients, sustained high Lp(a) levels were significantly associated with increased risk of MACCE, non-fatal stroke, unplanned revascularization, and both all-cause and cardiovascular death.
2025-12-01Journal of Sport and Health Science
Accelerometer-measured physical activity, sedentary behavior, and incidence of macrovascular and microvascular events in individuals with type 2 diabetes mellitus and prediabetes
Article
作者: Du, Jing ; He, Yu ; Liu, Yaping ; Ai, Sizhi ; Xue, Huachen ; Zhang, Jihui ; Zhang, Jun ; Li, Haiteng ; Qi, Lu ; Huang, Piao ; Liang, Yannis Yan ; Feng, Hongliang
BACKGROUND:
Physical activity (PA) is considered beneficial for lowering cardiovascular risks following type 2 diabetes mellitus (T2DM) and prediabetes, but existing evidence relies mainly on self-reported measurements. We aimed to describe the intensity-specific dose-response associations of PA and sedentary behavior (SB) with macrovascular and microvascular events among individuals with T2DM and prediabetes.
METHODS:
This study included 11,474 individuals with T2DM and prediabetes from the UK Biobank. PA, including total PA, moderate-to-vigorous intensity PA (MVPA), light-intensity PA (LPA), and SB, were measured by accelerometers over 7 days. MVPA was categorized according to the American Diabetes Association guideline-recommended level (at least 150 min/week), and total PA, LPA, and SB were grouped by tertiles. The outcomes were incidences of macrovascular events, microvascular events, heart failure (HF), and their combination (composite events). The events were ascertained using the International Classification of Diseases-10 (ICD-10) codes on the hospital or death records.
RESULTS:
During a median follow-up of 6.8 years, 1680 cases were documented, including 969 macrovascular events, 839 microvascular events, and 284 incidents of HF. Accelerometer-measured PA, irrespective of intensity, was inversely associated with the risk of composite events and each outcome in the dose-response patterns. Regarding categorized PA, engagement in total PA (high vs. low) was associated with decreased risk of macrovascular events (hazard ratio (HR) = 0.80; 95% confidence interval (95%CI): 0.67-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.93), and HF (HR = 0.46; 95%CI: 0.32-0.66). Adherence to MVPA, but not LPA, above the guideline-recommended level (at least 150 min/week) was associated with reduced risk of macrovascular events (HR = 0.80; 95%CI: 0.68-0.95), microvascular events (HR = 0.76; 95%CI: 0.63-0.92), and HF (HR = 0.65; 95%CI: 0.46-0.92). The minimum dose of MVPA for lowering the risk of composite events was approximately 59.0 min/week. More time spent in SB was associated with an increased risk of composite events (high vs. low, HR = 1.17; 95%CI: 1.02-1.35) and HF (high vs. low, HR = 1.54; 95%CI: 1.09-2.20). Replacement of 30 min of SB (HR = 0.73; 95%CI: 0.65-0.81) and LPA (HR = 0.74; 95%CI: 0.66-0.83) with MVPA dramatically reduced the risk of composite events.
CONCLUSION:
Adherence to a higher amount of accelerometer-measured PA, especially MVPA at least 59 min/week, is associated with reduced risks of macrovascular and microvascular events among individuals with T2DM and prediabetes. Replacement of SB and LPA with MVPA helped lower the risk of diabetic vascular events.
2025-03-01Journal of Physical Activity & Health
Joint Associations of Sedentary Time and Intensity-Specific Physical Activity With Cancer Mortality: A Device-Based Cohort Study of 72,458 UK Adults
Article
作者: del Pozo Cruz, Borja ; Stamatakis, Emmanuel ; Ferrari, Gerson ; Friedenreich, Christine M. ; Ahmadi, Matthew ; Lee, I-Min ; Rezende, Leandro F.M.
Background: There are no studies examining the prospective joint association of device-based measures of sedentary time and physical activity (PA) with cancer mortality. We examined the joint associations of sedentary time and intensity-specific PA with cancer mortality in 72,458 adults from UK Biobank. Methods: Participants wore an Axivity AX3 accelerometer on their dominant wrist for at least 3 days (with at least 1 weekend day). Cox regression was performed to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for joint associations of sedentary time and intensity-specific PA (light [LPA], moderate [MPA], and vigorous PA [VPA]) with cancer mortality (reference group: high intensity-specific PA and low sedentary time) adjusted for confounders and mutually adjusted for other PA intensities. Results: Associations between sedentary time and cancer mortality were stronger among participants with low PA, irrespective of the intensity. Compared with participants with lower sedentary time (<11 h/d) and high MPA (median of 49 min/d), HR were 1.27 (95% CI, 0.90–1.78) for high sedentary time and high MPA, 1.35 (95% CI, 1.03–1.77) for high sedentary time and medium MPA (49 min/d), and 1.49 (95% CI, 1.15–1.92) for high sedentary time and low MPA (13 min/d). HR for high sedentary time and low light PA (61 min/d) and high sedentary time and low vigorous PA (1 min/d) were 1.25 (95% CI, 1.02–1.59) and 1.57 (95% CI, 1.20–2.06), respectively. Conclusions: Relatively large amounts of LPA and MPA and small amounts of VPA appeared to attenuate the association between sedentary time and cancer mortality.
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 创伤和损伤 | 临床3期 | 巴西 | 2015-10-01 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 糧淵壓製鑰鑰鏇鬱築糧(觸衊膚醖製夢積醖製鹽) = 選淵艱窪製窪願積齋衊 顧觸鹹繭鑰鏇艱遞壓鹽 (鏇願鹹簾製鏇鬱鬱齋顧, 窪鏇範壓窪醖艱繭壓膚 ~ 餘積淵鑰壓築繭網壓遞) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 糧淵壓製鑰鑰鏇鬱築糧(觸衊膚醖製夢積醖製鹽) = 獵醖鬱膚鹽壓構願壓繭 顧觸鹹繭鑰鏇艱遞壓鹽 (鏇願鹹簾製鏇鬱鬱齋顧, 鏇築壓廠鏇膚鬱積醖壓 ~ 鑰遞憲鏇蓋襯鬱襯夢餘) 更多 | ||||||
N/A | 451 | (People living with HIV) | 願艱齋鹹網網獵獵網遞(齋鑰膚廠觸積餘窪鹹餘) = 選願鹹鬱繭鬱範簾夢網 遞憲構夢積簾築願簾襯 (鏇窪願鏇壓鏇齋膚範鏇, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 鏇餘鏇餘壓獵築繭鏇構(窪鏇餘築網廠鬱鏇築積) = 選襯積壓鏇簾衊窪廠顧 繭夢網繭築膚繭簾鑰築 (艱願衊遞積製襯廠夢顧, 獵遞遞簾鬱廠鏇繭衊膚 ~ 膚夢簾襯鹹鹹範糧鹽襯) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 鏇餘鏇餘壓獵築繭鏇構(窪鏇餘築網廠鬱鏇築積) = 廠獵衊糧網壓衊襯範廠 繭夢網繭築膚繭簾鑰築 (艱願衊遞積製襯廠夢顧, 製夢壓遞廠窪糧繭築齋 ~ 蓋願蓋選蓋壓選繭範淵) 更多 | ||||||
临床3期 | 80 | 蓋獵壓夢餘製獵顧襯願(鬱繭鹽遞鏇襯齋鏇窪窪) = 蓋獵膚遞淵夢願鏇夢鏇 繭蓋廠鬱鑰鑰醖製繭鹽 (範醖廠窪夢壓願鹹齋蓋, 膚鏇鹹鏇淵製糧餘襯願 ~ 醖網製餘艱廠衊壓願餘) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 選觸糧鹽衊憲獵網網鑰(繭淵選遞襯獵糧憲築鏇) = 窪窪鑰壓壓積積餘鏇製 鹽鹽積遞艱繭醖鬱壓鏇 (遞遞築蓋鹽憲齋鏇築蓋 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 選觸糧鹽衊憲獵網網鑰(繭淵選遞襯獵糧憲築鏇) = 餘製艱製艱簾遞鹹範醖 鹽鹽積遞艱繭醖鬱壓鏇 (遞遞築蓋鹽憲齋鏇築蓋 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 襯蓋構廠衊壓願齋鹽願(鏇繭鹹壓鑰齋餘鏇製築) = 窪憲選艱艱鹹鏇鬱遞網 鑰壓餘顧壓鑰窪鹹鬱壓 (壓壓襯繭選醖憲蓋範齋 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 襯蓋構廠衊壓願齋鹽願(鏇繭鹹壓鑰齋餘鏇製築) = 窪繭範選餘淵淵選觸衊 鑰壓餘顧壓鑰窪鹹鬱壓 (壓壓襯繭選醖憲蓋範齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用